Karl Wallendszus

4.2k total citations
20 papers, 611 citations indexed

About

Karl Wallendszus is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Economics and Econometrics. According to data from OpenAlex, Karl Wallendszus has authored 20 papers receiving a total of 611 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cardiology and Cardiovascular Medicine, 7 papers in Surgery and 4 papers in Economics and Econometrics. Recurrent topics in Karl Wallendszus's work include Lipoproteins and Cardiovascular Health (6 papers), Antiplatelet Therapy and Cardiovascular Diseases (5 papers) and Retinal Diseases and Treatments (3 papers). Karl Wallendszus is often cited by papers focused on Lipoproteins and Cardiovascular Health (6 papers), Antiplatelet Therapy and Cardiovascular Diseases (5 papers) and Retinal Diseases and Treatments (3 papers). Karl Wallendszus collaborates with scholars based in United Kingdom, Australia and United States. Karl Wallendszus's co-authors include Jane Armitage, Rory Collins, Anthony Keech, Jillian R. Mann, F. Raafat, Dorothy Pearson, Janet M. Barnes, Ann Barrett, Amy Lawson and William Stevens and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Journal of the American College of Cardiology.

In The Last Decade

Karl Wallendszus

20 papers receiving 580 citations

Peers

Countries citing papers authored by Karl Wallendszus

Since Specialization

Citations

This map shows the geographic impact of Karl Wallendszus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karl Wallendszus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karl Wallendszus more than expected).

Fields of papers citing papers by Karl Wallendszus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karl Wallendszus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karl Wallendszus. The network helps show where Karl Wallendszus may publish in the future.

Co-authorship network of co-authors of Karl Wallendszus

This figure shows the co-authorship network connecting the top 25 collaborators of Karl Wallendszus. A scholar is included among the top collaborators of Karl Wallendszus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karl Wallendszus. Karl Wallendszus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England 2024 ·Trials ·Guilherme Pessoa-Amorim, Raph Goldacre, Charles Crichton, Will Stevens, Michelle Nunn, Andy J. King, (unknown), (unknown), Heather Pinches, Andrew Rees, Eva Morris, Martin Landray, Richard Haynes, (unknown), Karl Wallendszus, Leon Peto, Mark Campbell, Charlie Harper, Marion Mafham	3
2	Effect of Fenofibrate on Progression of Diabetic Retinopathy 2024 ·NEJM Evidence ·David Preiss, Jennifer Logue, Emily Sammons, (unknown), Jonathan Emberson, Rachel Wade, Karl Wallendszus, Will Stevens, (unknown), Simon Harding, Graham Leese, Gemma Currie, Jane Armitage	25
3	ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration 2023 ·Contemporary Clinical Trials Communications ·Emily Sammons, Louise Bowman, William Stevens, Georgina Buck, Karl Wallendszus, (unknown), Sarah Parish, Jane Armitage	3
4	Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data 2023 ·Heart ·Charlie Harper, Marion Mafham, William G. Herrington, Natalie Staplin, William Stevens, Karl Wallendszus, Richard Haynes, Martin Landray, Sarah Parish, Louise Bowman, Jane Armitage	5
5	Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial 2022 ·European Heart Journal ·Sarah Parish, Marion Mafham, Alison Offer, Jill Barton, Karl Wallendszus, William Stevens, Georgina Buck, Richard Haynes, Rory Collins, Louise Bowman, Jane Armitage	27
6	Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial–Adjudicated Direct Follow-up Data in the UK 2021 ·JAMA Network Open ·Charlie Harper, Marion Mafham, William G. Herrington, Natalie Staplin, William Stevens, Karl Wallendszus, Richard Haynes, Martin Landray, Sarah Parish, Louise Bowman, Jane Armitage	19
7	Effects of aspirin for primary prevention in persons with diabetes mellitus: the ASCEND Study Collaborative Group 2018 ·Journal of Vascular Surgery ·Louise Bowman, Marion Mafham, Karl Wallendszus, W. Grant Stevens, Georgina Buck, Jill Barton	21
8	Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease 2017 ·Journal of Vascular Surgery ·Lee Bowman, Jemma C. Hopewell, (unknown), Karl Wallendszus, William Stevens	36
9	Can vascular mortality be reliably ascertained from the underlying cause of death recorded on a medical death certificate? Evidence from 2800 adjudicated heart protection study (HPS) deaths 2015 ·Trials ·William G. Herrington, Karl Wallendszus, Louise Bowman, Martin Landray, Jane Armitage	1
10	MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS 2007 ·Journal of the American College of Cardiology ·Richard Bulbulia, (unknown), Karl Wallendszus, Sarah Parish, (unknown), R Collins	2
11	Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids 1997 ·European Heart Journal ·K.A. Mitropoulos, J. M. Armitage, Rory Collins, T W Meade, B. E. A. Reeves, Karl Wallendszus, (unknown), Adam Lawson, Richard Peto, (unknown)	65
12	Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration 1996 ·BMJ ·Jane Wardle, Jane Armitage, Rory Collins, Karl Wallendszus, Anthony Keech, Amy Lawson	71
13	Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo‐controlled study 1996 ·British Journal of Clinical Pharmacology ·Anthony Keech, Jane Armitage, Karl Wallendszus, Amy Lawson, (unknown), Sarah Parish, Rory Collins	16
14	Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study 1996 ·British Journal of Clinical Pharmacology ·Anthony Keech, Jane Armitage, Karl Wallendszus, Adam Lawson, (unknown), Sarah Parish, (unknown)	13
15	Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. 1995 ·British Journal of Ophthalmology ·Martin L. Harris, Anthony J. Bron, Nicola Brown, Anthony Keech, Karl Wallendszus, Jane Armitage, Stephen MacMahon, Grant R. Snibson, Rory Collins	48
16	Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study 1994 ·European Heart Journal ·Anthony Keech, Richard Collins, Stephen MacMahon, Jane Armitage, (unknown), Karl Wallendszus, Marzieh Fatemian, E. Kearney, (unknown), Jennifer S. Mindell, J N Mount, Richard W. Painter, Sarah Parish, B M Slavin, Peter Sleight, Linda Youngman, Richard Peto, (unknown)	80
17	Hepatopathy-thrombocytopenia syndrome--a complication of dactinomycin therapy for Wilms' tumor: a report from the United Kingdom Childrens Cancer Study Group. 1991 ·Journal of Clinical Oncology ·June Raine, A. Bowman, Karl Wallendszus, Jon Pritchard	34
18	Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen) 1990 ·British Journal of Cancer ·(unknown), CR Pinkerton, JM Zucker, Olivier Hartmann, Jon Pritchard, Valerie Broadbent, P. H. Morris‐Jones, F. Breatnach, (unknown), A. D. J. Pearson, Karl Wallendszus	29
19	Results of the United Kingdom children's cancer study group's malignant germ cell tumor studies 1990 ·Cancer ·Jillian R. Mann, Dorothy Pearson, Ann Barrett, F. Raafat, Janet M. Barnes, Karl Wallendszus	109
20	GENDER AND SURVIVAL IN NEUROBLASTOMA 1989 ·The Lancet ·Jon Pritchard, Justin M. Barnes, (unknown), Karl Wallendszus	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact